After Leaping 27% Hyloris Pharmaceuticals SA (EBR:HYL) Shares Are Not Flying Under The Radar
Mar 22
Have your own idea? Try our Stock Screener
Belgian (BEL20) Healthcare Sector Analysis
UpdatedApr 26, 2025
DataAggregated Company Financials
Companies13
- 7D5.6%
- 3M-17.3%
- 1Y32.5%
- YTD-16.7%
Over the last 7 days, the Healthcare industry has risen 4.3%, driven by gains from UCB of 8.1%. Meanwhile, Hyloris Pharmaceuticals actually underperformed within the industry, shrinking 5.3% in the last week. In the last 12 months, the industry was up 31%. Looking forward, earnings are forecast to grow by 24% annually.
Sector Valuation and Performance
Has the Belgian Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 26 Apr 2025 | €68.9b | €10.7b | €1.8b | 40.7x | 38.7x | 6.5x |
| Mon, 24 Mar 2025 | €77.5b | €10.8b | €1.9b | 42.6x | 40.6x | 7.2x |
| Wed, 19 Feb 2025 | €81.4b | €9.7b | €270.2m | 62.6x | 301.1x | 8.3x |
| Fri, 17 Jan 2025 | €83.9b | €9.8b | €269.7m | 60.4x | 311.2x | 8.6x |
| Sun, 15 Dec 2024 | €77.8b | €9.7b | €270.4m | 59.1x | 287.8x | 8x |
| Tue, 12 Nov 2024 | €77.5b | €9.7b | €271.9m | 61.6x | 284.9x | 8x |
| Thu, 10 Oct 2024 | €68.3b | €9.4b | €130.3m | 58.1x | 524x | 7.2x |
| Sat, 07 Sep 2024 | €67.6b | €9.4b | €96.3m | 50.7x | 701.9x | 7.2x |
| Mon, 05 Aug 2024 | €64.3b | €9.3b | €52.3m | 60x | 1229.5x | 6.9x |
| Wed, 03 Jul 2024 | €58.0b | €8.9b | €35.3m | 53.9x | 1644.1x | 6.5x |
| Fri, 31 May 2024 | €51.2b | €8.9b | €37.7m | 49x | 1358.2x | 5.8x |
| Sun, 28 Apr 2024 | €51.2b | €8.8b | €59.3m | 47.8x | 864.6x | 5.9x |
| Tue, 26 Mar 2024 | €50.4b | €8.7b | €40.8m | 46.6x | 1234.3x | 5.8x |
| Thu, 22 Feb 2024 | €46.0b | €9.1b | -€83,127,239.40 | 41x | -553.1x | 5x |
| Sat, 20 Jan 2024 | €40.8b | €9.1b | -€125,749,269.00 | 37.8x | -324.2x | 4.5x |
| Mon, 18 Dec 2023 | €44.3b | €9.1b | -€125,684,761.00 | 35.6x | -352.5x | 4.9x |
| Wed, 15 Nov 2023 | €45.0b | €9.1b | -€140,810,122.00 | 31.1x | -319.7x | 4.9x |
| Fri, 13 Oct 2023 | €49.0b | €9.0b | -€305,078,582.00 | 35.2x | -160.7x | 5.5x |
| Sun, 10 Sep 2023 | €49.9b | €9.0b | -€359,434,002.00 | 35x | -138.9x | 5.5x |
| Tue, 08 Aug 2023 | €47.2b | €9.0b | -€328,634,029.00 | 40.7x | -143.6x | 5.3x |
| Thu, 06 Jul 2023 | €40.7b | €9.1b | -€353,002,667.00 | 36.4x | -115.2x | 4.5x |
| Sat, 03 Jun 2023 | €42.5b | €9.1b | -€359,484,305.00 | 37.3x | -118.2x | 4.7x |
| Mon, 01 May 2023 | €41.9b | €8.9b | -€264,857,485.00 | 27.9x | -158.3x | 4.7x |
| Wed, 29 Mar 2023 | €40.2b | €8.9b | -€275,963,964.00 | 26.1x | -145.8x | 4.5x |
| Fri, 24 Feb 2023 | €40.9b | €9.1b | €131.0m | 16.3x | 312x | 4.5x |
| Sun, 22 Jan 2023 | €40.7b | €9.0b | €131.4m | 15.4x | 310.1x | 4.5x |
| Tue, 20 Dec 2022 | €39.9b | €9.0b | €112.3m | 14.4x | 355.4x | 4.4x |
| Thu, 17 Nov 2022 | €40.0b | €9.0b | €93.3m | 14.5x | 428.8x | 4.4x |
| Sat, 15 Oct 2022 | €40.4b | €8.9b | €45.2m | 13.9x | 895.3x | 4.6x |
| Mon, 12 Sep 2022 | €41.6b | €8.8b | €53.1m | 14.5x | 783.4x | 4.7x |
| Wed, 10 Aug 2022 | €41.1b | €8.8b | €189.7m | 15.2x | 216.4x | 4.7x |
| Fri, 08 Jul 2022 | €43.0b | €8.9b | €588.5m | 16.6x | 73.1x | 4.8x |
| Sun, 05 Jun 2022 | €38.7b | €8.9b | €654.7m | 17x | 59.1x | 4.4x |
| Tue, 03 May 2022 | €43.2b | €9.0b | €820.4m | 19.9x | 52.7x | 4.8x |
Price to Earnings Ratio
52.7x
Current Industry PE
- Investors are pessimistic on the Belgian Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 38.3x which is lower than its 3-year average PE of 289x.
- The 3-year average PS ratio of 5.6x is lower than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have grown 29% per year over the last three years.
- Revenues for these companies have grown 5.9% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Belgian Healthcare sector?
| BE Market | 1.79% | |
| Healthcare | 5.56% | |
| Pharma | 9.36% | |
| Medical Equipment | 2.93% | |
| Biotech | 2.20% | |
| Healthtech | 1.36% | |
| Healthcare Services | 0.21% | |
| Life Sciences | 0% | 0 |
Industry PE
- Investors are most optimistic about the Biotech industry which is trading above its 3-year average PE ratio.
- Analysts are expecting annual earnings growth of 28.5% and investors are willing to pay a premium for that growth.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 111% over the next 5 years.
- In contrast, the Healthcare Services industry is expected to see its earnings grow by 12% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| UCB UCB | €149.70 | 9.8% +€2.5b | 20.2% | PE26.7x | |
| ARGX argenx | €535.80 | 2.2% +€708.3m | 53.4% | PE44.7x | |
| TUB Financière de Tubize | €118.40 | 7.4% +€365.0m | 25.2% | PE58.5x | |
| IBAB Ion Beam Applications | €10.54 | 6.0% +€17.3m | -18.0% | PE38.8x | |
| ONWD Onward Medical | €4.02 | 5.2% +€8.9m | -14.4% | PS105.4x |